US EditionDizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025
- On May 26, 2025, Dizal shared clinical trial findings for its investigational agents DZD8586 and DZD6008 during the ASCO Annual Meeting held in Shanghai.
- These presentations stem from phase I/II studies addressing resistance in hematologic malignancies and EGFR-mutated NSCLC patients with limited existing treatments.
- DZD8586 achieved a response in 84.2% of heavily treated CLL/SLL patients, including those harboring BTK resistance mutations, while DZD6008 exhibited sustained antitumor effects alongside a favorable safety profile in patients with EGFR-mutated NSCLC.
- DZD8586 targets both BTK-dependent and-independent pathways with a 9-month duration of response rate of 83.3%, and DZD6008 achieved target lesion shrinkage in 83.3% of enrolled patients, per oral abstracts presented.
- These data reinforce Dizal's R&D strengths and support advancing both therapies to address unmet needs in blood cancers and lung cancer resistant to current treatments.
13 Articles
13 Articles
Morgan County Citizen
Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025
DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with ORR of 84.2%DZD6008, a BBB-penetrant 4th generation EGFR TKI, showed encouraging and durable anti-tumor activity with favorable safety and tolerability as a monotherapy in…
Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025 - PressReach
DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with ORR of 84.2% DZD6008, a BBB-penetrant 4th generation EGFR TKI, showed encouraging and durable anti-tumor activity with favorable safety and tolerability as a monotherapy in heavily pre-treated non-small cell lung cancer (NSCLC) patients with EGFR-mutations SHANGHAI, May 26, 2025 /PRNewswire/ —…
Coverage Details
Bias Distribution
- 40% of the sources lean Left, 40% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage